Survival in patients with neuroendocrine tumors after treatment with [Y-90-DOTA,Tyr(3)]octreotide in a phase-1 study.

Valkema, R; Pauwels, Stanislas; Jamar, François; Kvols, L; Smith, C; Krenning, EP

Survival in patients with neuroendocrine tumors after treatment with [Y-90-DOTA,Tyr(3)]octreotide in a phase-1 study.

Valkema, R

;

Pauwels, Stanislas

;

Jamar, François

;

Kvols, L

;

Krenning, EP

;et.al.

(2003) 50th Annual Meeting of the Society-of-Nuclear-Medicine — Location: NEW ORLEANS (Louisiana) (21.June.2003)

Files

No attached file found for this publication.

Details

Authors

Valkema, R
Author
Pauwels, StanislasUCLouvain
Author
Jamar, FrançoisUCLouvain
Author
Kvols, L
Author
Krenning, EP
Author

Affiliations

UCLouvainCliniques universitaires Saint-Luc
UCLouvainMD/MINT - Département de médecine interne

Citations

APA
Chicago
FWB

Valkema, R., Pauwels, S., Jamar, F., Kvols, L., Smith, C., & Krenning, E. (2003). Survival in patients with neuroendocrine tumors after treatment with [Y-90-DOTA,Tyr(3)]octreotide in a phase-1 study. The Journal of Nuclear Medicine, 44(5), 136P-136P. https://hdl.handle.net/2078.5/63788 (Original work published 2003)